Hypothesis-Generating Brief: Vascular age

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Recode directional findings to match source abstracts: Sheng 2025 (positive for ePWV→CAD), Nguyen 2026 (positive for low-T/vascular dysfunction), Kakaletsis 2024 (positive prognostic for PWV in stroke), Luo 2025 (positive for L-citrulline/FMD), Azizzadeh 2026 (prevalence data with clear direction), Lu 2026 (positive for vascular age acceleration→CVD). Remove the '11/13 null' framing or relabel it as '11/13 coded at receipt level' with explicit distinction from source-level findings.
2. Reconcile the Evidence Landscape tables to include all 13 admitted sources; remove or replace the repetitive boilerplate subsection paragraphs with actual outcome-class findings.
3. Enumerate the 12 cross-study disagreements or replace the count with a qualitative description of where the disagreements lie (endpoint, population, direction).
4. Expand Key Findings to report concrete, bounded findings per outcome class drawn from the abstracts (e.g., prevalence of EVA, HRs for vascular age acceleration, meta-analytic FMD effect size), staying within what the abstracts actually support.
5. Tighten the Conclusion: the direct-source ceiling (Wang 2024, n=40) is too thin to anchor the closing claim; either broaden the direct tier to include well-powered observational/cohort sources (Azizzadeh, Lu, Sheng, Nguyen) as direct evidence for their respective outcome classes, or explicitly state the conclusion cannot be drawn.
6. Strengthen Gaps with at least 3 concrete, actionable next-step studies linked to the specific gaps in the current bundle (e.g., longitudinal vascular age model validation, RCT of L-citrulline in vascular aging phenotypes, cluster-based prognostic studies).

Major issues

• The source bundle contains abstracts that contradict several manuscript coding decisions: Sheng 2025 and Nguyen 2026 report clear positive directional findings (HR 1.50 for CAD, significant testosterone/vascular associations), yet the manuscript codes them as 'direction=null' and describes the corpus as 'non-supportive for clinical efficacy.' The claim_evidence_alignment is therefore materially weaker than the actual source content warrants, and the evidence-honesty framing overcorrects toward null.
• Multiple sources in the bundle are coded incorrectly relative to their abstracts: Azizzadeh 2026 and Lu 2026 report clear prevalence and CVD-risk associations but do not appear in the Evidence Landscape tables or Key Findings cited sources; Kakaletsis 2024 is coded as review-level/unclear but the abstract reports concrete PWV prognostic data; Luo 2025 is a meta-analysis of 8 RCTs showing significant FMD improvement but is not foregrounded.
• The 'only 1 direct clinical source' (Wang 2024, n=40 postmenopausal women, 24-week Tai Chi RCT) is an extremely narrow evidentiary basis for the headline conclusion, yet the manuscript treats this thinness as an adequate bound rather than flagging it as a corpus-fit problem.
• Cross-study disagreement count of '12' is stated but never enumerated or characterized; this is a structural gap that prevents audit.
• The Evidence Landscape tables contain repetitive boilerplate ('remains a separate Results slice…') that adds no synthesis, and the Key Findings section is nearly empty, containing only the outcome-class note and source examples without any actual findings.

Minor issues

• Several bundle sources (Kozlik 2026, Lu 2026, Azizzadeh 2026, Rodilla 2026, Carmo 2025, Luo 2025, Kakaletsis 2024) are absent from the Evidence Landscape domain table even though they are part of the admitted 13.
• The Gaps section is generic ('run adequately powered studies') and does not identify which specific endpoint, population, or comparison is most actionable given the existing bundle.
• The Abstract repeats the evidence-honesty framing three times, diluting the actual content.
• Year fields for some sources (Nguyen 2026, Lu 2026, Azizzadeh 2026, Rodilla 2026, Kozlik 2026) show 2026, which is plausible given the retrieval date but should be verified.

Reviewer note

This rapid evidence synthesis on vascular age is structurally transparent about its protocol and tier system, but it suffers from a systematic mismatch between the coded directions in the manuscript and the actual content of the source bundle. The abstract coding claims '11/13 retained sources are coded as null or no extracted directional signal,' yet the bundled abstracts for Sheng 2025, Nguyen 2026, Kakaletsis 2024, Luo 2025, Azizzadeh 2026, and Lu 2026 all report concrete positive directional findings. This is a coding-integrity problem, not just a calibration choice. The Evidence Landscape tables repeat the same boilerplate paragraph across five outcome classes without reporting any actual findings, the Key Findings section is nearly empty, and the Gaps section is generic. The conclusion appropriately avoids clinical/policy escalation, but it overcorrects toward null by treating a bundle that contains several direct positive associations as 'non-supportive.' Several admitted sources (Kozlik, Lu, Azizzadeh, Rodilla, Carmo, Luo, Kakaletsis) are not represented in the Evidence Landscape domain table. The paper is salvageable: the search scope, tier system, and protocol transparency are genuine strengths, but the manuscript needs a comprehensive recoding pass against the actual abstracts, enumeration of the 12 disagreements, and substantive Key Findings drawn from the bundle. These are bounded but non-trivial edits, placing this firmly in revise territory rather than accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis